# Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

> clinical trial · VERIFIED · 2026-07-16

Status: RECRUITING · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Condition: Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

- Company: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07424222

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.